MX2020008454A - Composicion inmunogenica que comprende antigenos estafilococicos. - Google Patents
Composicion inmunogenica que comprende antigenos estafilococicos.Info
- Publication number
- MX2020008454A MX2020008454A MX2020008454A MX2020008454A MX2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic composition
- staphylococcal antigens
- staphylococcal
- antigens
- conjugates
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802339.0A GB201802339D0 (en) | 2018-02-13 | 2018-02-13 | Immunogenic composition |
| PCT/EP2019/053463 WO2019158537A1 (en) | 2018-02-13 | 2019-02-12 | Immunogenic composition comprising staphylococcal antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008454A true MX2020008454A (es) | 2021-03-25 |
Family
ID=61731342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008454A MX2020008454A (es) | 2018-02-13 | 2019-02-12 | Composicion inmunogenica que comprende antigenos estafilococicos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11426455B2 (https=) |
| EP (1) | EP3752183A1 (https=) |
| JP (1) | JP2021514387A (https=) |
| KR (1) | KR20200121825A (https=) |
| CN (1) | CN112153980A (https=) |
| AR (1) | AR114627A1 (https=) |
| AU (1) | AU2019221496B2 (https=) |
| BR (1) | BR112020016373A2 (https=) |
| CA (1) | CA3090609A1 (https=) |
| EA (1) | EA202091690A1 (https=) |
| GB (1) | GB201802339D0 (https=) |
| IL (1) | IL276661B2 (https=) |
| MX (1) | MX2020008454A (https=) |
| SG (1) | SG11202007676RA (https=) |
| WO (1) | WO2019158537A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CN110511950B (zh) * | 2019-07-29 | 2022-03-08 | 因之彩生物科技（武汉）有限公司 | Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用 |
| EP3777884A1 (en) * | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2021122551A1 (en) | 2019-12-19 | 2021-06-24 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
| MY207887A (en) * | 2020-05-01 | 2025-03-26 | Sinocelltech Ltd | Method for improving immunogenicity of protein/peptide antigen |
| JP7423133B2 (ja) | 2020-09-21 | 2024-01-29 | エルジー エナジー ソリューション リミテッド | リチウム二次電池の活性化方法及びリチウム二次電池 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ553776A (en) * | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
| GB0526038D0 (en) | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| SG188102A1 (en) * | 2008-01-31 | 2013-03-28 | Trinity College Dublin | Treatment of microbial infections |
| AU2015202532A1 (en) | 2009-04-14 | 2015-06-04 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
| SA110310528B1 (ar) * | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| US20140037650A1 (en) | 2009-07-24 | 2014-02-06 | University Of Chicago | Compositions and methods related to antibodies to staphylococcal proteins isda or isdb |
| EP3281639B1 (en) * | 2010-05-06 | 2020-11-11 | GlaxoSmithKline Biologicals S.A. | Capsular gram-positive bacteria bioconjugate vaccines |
| CA2803298C (en) * | 2010-07-02 | 2020-07-14 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
| EP2614074A1 (en) | 2010-09-09 | 2013-07-17 | The University of Chicago | Methods and compositions involving protective staphylococcal antigens |
| EP2654784B1 (en) | 2010-12-22 | 2016-12-07 | Wyeth LLC | Stable immunogenic compositions of staphylococcus aureus antigens |
| BR112014003315A2 (pt) * | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| US10195262B2 (en) | 2013-12-04 | 2019-02-05 | Glaxosmithkline Biologicals S.A. | Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli |
| CN106103469B (zh) * | 2014-03-26 | 2020-11-27 | 葛兰素史密丝克莱恩生物有限公司 | 突变型葡萄球菌抗原 |
| GB201721576D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
-
2018
- 2018-02-13 GB GBGB1802339.0A patent/GB201802339D0/en not_active Ceased
-
2019
- 2019-02-12 JP JP2020565545A patent/JP2021514387A/ja active Pending
- 2019-02-12 SG SG11202007676RA patent/SG11202007676RA/en unknown
- 2019-02-12 WO PCT/EP2019/053463 patent/WO2019158537A1/en not_active Ceased
- 2019-02-12 CN CN201980025676.7A patent/CN112153980A/zh active Pending
- 2019-02-12 EP EP19706423.1A patent/EP3752183A1/en not_active Withdrawn
- 2019-02-12 BR BR112020016373-2A patent/BR112020016373A2/pt not_active IP Right Cessation
- 2019-02-12 MX MX2020008454A patent/MX2020008454A/es unknown
- 2019-02-12 CA CA3090609A patent/CA3090609A1/en active Pending
- 2019-02-12 KR KR1020207025858A patent/KR20200121825A/ko not_active Withdrawn
- 2019-02-12 IL IL276661A patent/IL276661B2/en unknown
- 2019-02-12 AR ARP190100345A patent/AR114627A1/es not_active Application Discontinuation
- 2019-02-12 US US16/968,895 patent/US11426455B2/en active Active
- 2019-02-12 EA EA202091690A patent/EA202091690A1/ru unknown
- 2019-02-12 AU AU2019221496A patent/AU2019221496B2/en not_active Ceased
-
2022
- 2022-07-20 US US17/869,055 patent/US20230052495A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11426455B2 (en) | 2022-08-30 |
| EA202091690A1 (ru) | 2020-11-27 |
| US20230052495A1 (en) | 2023-02-16 |
| WO2019158537A1 (en) | 2019-08-22 |
| CN112153980A (zh) | 2020-12-29 |
| KR20200121825A (ko) | 2020-10-26 |
| IL276661B2 (en) | 2023-08-01 |
| EP3752183A1 (en) | 2020-12-23 |
| US20210023192A1 (en) | 2021-01-28 |
| AR114627A1 (es) | 2020-09-30 |
| CA3090609A1 (en) | 2019-08-22 |
| AU2019221496B2 (en) | 2022-12-08 |
| AU2019221496A1 (en) | 2020-08-27 |
| BR112020016373A2 (pt) | 2020-12-15 |
| GB201802339D0 (en) | 2018-03-28 |
| IL276661A (en) | 2020-09-30 |
| IL276661B1 (en) | 2023-04-01 |
| SG11202007676RA (en) | 2020-09-29 |
| JP2021514387A (ja) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| PH12021550318A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| MX392525B (es) | Composiciones inmunogenicas para su uso en vacunas neumococicas | |
| MX2024006606A (es) | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos. | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX395525B (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
| PH12018500037A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
| GEAP202115055A (en) | Anti-cd27 antibodies | |
| TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
| BR112016012599A2 (pt) | composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus | |
| MX2021015533A (es) | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. | |
| MX2024013161A (es) | Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs) | |
| MX379201B (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2019015007A (es) | Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. | |
| MX2021002909A (es) | Vacunas de proteinas de fusion neumococicas. | |
| MA45283B1 (fr) | Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela | |
| MX2021005421A (es) | Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos. | |
| MX2021005423A (es) | Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos. | |
| MX2022001937A (es) | Composicion inmunogenica. | |
| BR112022000417A2 (pt) | Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv | |
| MX2017016858A (es) | Composiciones inmunogenicas. | |
| MX2022008036A (es) | Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv. | |
| WO2020071869A8 (ko) | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 | |
| EP4361262A3 (en) | Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis | |
| JO3420B1 (ar) | تركيبة صيدلانية ولقاح للوقاية من اصابات المكورة العقدية |